These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 5329616)
21. [The treatment of essential hyperlipidemia with clofibrate]. Reuter W; Seifert A Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619 [No Abstract] [Full Text] [Related]
22. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA; 1972 May; 220(7):996-1008. PubMed ID: 4337170 [No Abstract] [Full Text] [Related]
24. Essential hyperlipemia with xanthomatosis: effects of cholestyramine and clofibrate. Roe DA Arch Dermatol; 1968 Apr; 97(4):436-45. PubMed ID: 5643239 [No Abstract] [Full Text] [Related]
25. Diet and drugs in the treatment of hyperlipidemias. Med Lett Drugs Ther; 1970 May; 12(10):42-4. PubMed ID: 5514225 [No Abstract] [Full Text] [Related]
26. Drug therapy of hyperlipoproteinemia. Levy RI JAMA; 1976 May; 235(21):2334-6. PubMed ID: 946632 [No Abstract] [Full Text] [Related]
27. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Stamler J Adv Exp Med Biol; 1977; 82():52-75. PubMed ID: 335823 [No Abstract] [Full Text] [Related]
34. Effects of dextrothyroxine on serum lipoprotein and cholesterol levels. Searcy RL; Hungerford DA; Low EM Curr Ther Res Clin Exp; 1968 Apr; 10(4):177-86. PubMed ID: 4967872 [No Abstract] [Full Text] [Related]
35. [Clinical testing of a combination of clofibrate and beta-pyridylcarbinol in an unusual dosis relation]. Mann S; Maisenbacher HJ Z Allgemeinmed; 1975 Aug; 51(24):1066-71. PubMed ID: 1101545 [No Abstract] [Full Text] [Related]
36. Aggressive medical therapy for the prevention and treatment of coronary artery disease. Malloy MJ; Kane JP Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050 [No Abstract] [Full Text] [Related]
37. The effect on serum tocopherol levels of drug-induced decrease in serum lipids. Weiss P; Bianchine JR Am J Med Sci; 1969 Oct; 258(4):275-81. PubMed ID: 5823464 [No Abstract] [Full Text] [Related]
38. Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate. Olsson AG; Orö L; Rössner S Atherosclerosis; 1974; 19(3):407-15. PubMed ID: 4364073 [No Abstract] [Full Text] [Related]
39. Clinical trial of methyl clofenapate (a derivative of clofibrate) in patients with essential hyperlipidaemias--with special reference to type II (primary) hyperlipidaemia. Craig GM; Walton KW Atherosclerosis; 1972; 15(2):189-98. PubMed ID: 4579956 [No Abstract] [Full Text] [Related]
40. [Medical treatment of hyperlipemia. Indications and modern preparations]. Frey H Tidsskr Nor Laegeforen; 1968 Jan; 88(2):6-8. PubMed ID: 5663311 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]